Core Viewpoint - Investors with significant losses in BioAge Labs, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company due to alleged misleading statements regarding clinical trials and safety concerns [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that BioAge failed to disclose potential liver transaminitis from previous clinical Phase 1 trials and preclinical toxicology studies [3]. - It is claimed that there were safety concerns with the ongoing STRIDES clinical trial that were not communicated to investors [3]. - The company allegedly overstated the likelihood of completing the STRIDES study and the potential of a second Phase 2 clinical trial involving azelaprag and semaglutide for treating obesity in individuals aged 18 and older [3]. - Defendants' positive statements about the company's business and prospects were said to be materially misleading and lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses in BioAge Labs, Inc. are encouraged to contact the Law Offices of Howard G. Smith before March 10, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals may retain counsel of their choice or remain absent members of the class action without taking any immediate action [5].

Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. (BIOA), with a deadline of March 10, 2025, for individuals to join the action [1] Company Summary - The lawsuit indicates potential legal challenges for BioAge Labs, Inc., which may impact its financial standing and market perception [1] - The firm is currently facing scrutiny that could affect its operations and investor confidence [1] Industry Summary - The filing of class action lawsuits in the biotech sector highlights ongoing legal risks that companies in this industry may encounter [1] - Such legal actions can lead to increased regulatory scrutiny and may influence investment decisions within the biotech industry [1]

Core Viewpoint - Shareholders of BioAge Labs, Inc. (BIOA) who have incurred losses are encouraged to contact Levi & Korsinsky regarding a pending class action lawsuit [1] Group 1 - The class action is aimed at addressing the financial losses suffered by shareholders of BioAge Labs, Inc. [1] - The law firm Levi & Korsinsky is representing the interests of the affected shareholders [1] - The announcement highlights the potential for legal recourse for investors who believe they have been wronged [1]

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky ...

BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! ...

BIOA DEADLINE: The March 10 BioAge Labs Class Action Deadline is Approaching - Contact BFA Law if You Suffered Losses ...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc.(BIOA) Shareholders ...

Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA ...

BioAge Labs, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm ...